Парадоксы безопасности изотретиноина: баланс между нежелательными явлениями и клинической необходимостью
Ольховская К.Б., Круглова Л.С., Константиновская Е.Е., Кениксфест Ю.В.
Системный изотретиноин остается высокоэффективным стандартом лечения тяжелого акне, воздействуя на ключевые звенья патогенеза. Однако его применение сопряжено с широким спектром нежелательных явлений, создавая парадокс безопасности. В научном обзоре проанализированы имеющиеся к настоящему моменту данные о возможных побочных эффектах терапии системным изотретиноином.
Для цитирования: Ольховская К.Б., Круглова Л.С., Константиновская Е.Е., Кениксфест Ю.В. Парадоксы безопасности изотретиноина: баланс между нежелательными явлениями и клинической необходимостью. Фарматека. 2025;32(10):18-24. DOI: https://dx.doi.org/10.18565/pharmateca.2025.10.18-24
Вклад авторов: Все авторы принимали участие в разработке концепции статьи и написании рукописи. Окончательная версия рукописи была одобрена всеми авторами.
Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Финансирование: Работа выполнена без спонсорской поддержки.
Ключевые слова
акне
изотретиноин
безопасность
нежелательные явления
Список литературы
1. Hay R.J., Johns N.E., Williams H.C., et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–1534. https://dx.doi.org/10.1038/jid.2013.446
2. Williams H.C., Dellavalle R.P., Garner S. Acne vulgaris. The Lancet. 2012;379(9813):361–372. https://dx.doi.org/10.1016/s0140-6736(11)60321-8
3. Kurokawa I., Danby F.W., Ju Q., et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821–832. https://dx.doi.org/10.1111/j.1600-0625.2009.00890.x
4. O’Neill A.M., Liggins M.C., Seidman J.S., et al. Antimicrobial production by perifollicular dermal preadipocytes is essential to the pathophysiology of acne. Sci Transl Med. 2022;14(632):eabh1478. https://dx.doi.org/10.1126/scitranslmed.abh1478
5. Agrawal D.A., Khunger N. A Morphological study of acne scarring and its relationship between severity and treatment of active acne. J Cutan Aesthet Surg. 2020;13(3):210–216. https://dx.doi.org/10.4103/JCAS.JCAS_177_19
6. Drake L., Reyes-Hadsall S., Barbieri J.S., Mostaghimi A. New developments in topical acne therapy. Am J Clin Dermatol. 2022;23(2):125–136. https://dx.doi.org/10.1007/s40257-021-00666-9
7. Reynolds R.V., Yeung H., Cheng C.E., et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1–1006.e30. https://dx.doi.org/10.1016/j.jaad.2023.12.017
8. Круглова Л.С., Грязева Н.В. Современные подходы к терапии акне: обзор клинических рекомендаций и разбор клинических случаев. Медицинский алфавит. 2024;9:61–65.
9. Reinold J., Kollhorst B., Wentzell N., et al. Use of isotretinoin among girls and women of childbearing age and occurrence of isotretinoin-exposed pregnancies in Germany: а population-based study. PLoS Med. 2024;21(1):e1004339. https://dx.doi.org/10.1371/journal.pmed.1004339
10. Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162–169. https://dx.doi.org/10.4161/derm.1.3.9364
11. Thielitz A., Krautheim A., Gollnick H. Update in retinoid therapy of acne. Dermatol Ther. 2006;19(5):272–279. https://dx.doi.org/10.1111/j.1529-8019.2006.00084.x
12. Nelson A.M., Gilliland K.L., Cong Z., Thiboutot D.M. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol. 2006;126(10):2178–2189. https://dx.doi.org/10.1038/sj.jid.5700289
13. Melnik B.C. Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol. 2017;97(2):173–181. https://dx.doi.org/10.2340/00015555-2535
14. Shi G., Liao P.Y., Cai X.L., et al. FoxO1 enhances differentiation and apoptosis in human primary keratinocytes. Exp Dermatol. 2018;27(11):1254–1260. https://dx.doi.org/10.1111/exd.13775
15. Dispenza M.C., Wolpert E.B., Gilliland K.L., et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol. 2012;132(9):2198–2205. https://dx.doi.org/10.1038/jid.2012.111
16. Karadag A.S., Ertugrul D.T., Bilgili S.G., et al. Immunoregulatory effects of isotretinoin in patients with acne. Br J Dermatol. 2012;167(2):433–435. https://dx.doi.org/10.1111/j.1365-2133.2012.10949.x
17. Papakonstantinou E., Aletras A.J., Glass E., et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol. 2005;125(4):673–684. https://dx.doi.org/10.1111/j.0022-202X.2005.23848.x
18. Bagatin E., Costa C.S. The use of isotretinoin for acne - an update on optimal dosing, surveillance, and adverse effects. Expert Rev Clin Pharmacol. 2020;13(8):885–897. https://dx.doi.org/10.1080/17512433.2020.1796637
19. Vallerand I.A., Lewinson R.T., Farris M.S., et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178(1):76–85. https://dx.doi.org/10.1111/bjd.15668
20. Landis M.N. Optimizing isotretinoin treatment of acne: update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes. Am J Clin Dermatol. 2020;21(3):411–419. https://dx.doi.org/10.1007/s40257-020-00508-0
21. Ornelas J., Rosamilia L., Larsen L., et al. Objective assessment of isotretinoin-associated cheilitis: Isotretinoin Cheilitis Grading Scale. J Dermatolog Treat. 2016;27(2):153-155. https://dx.doi.org/10.3109/09546634.2015.1086477
22. Cassano N., De Benedittis M., Petruzzi M., et al. Topical Vitamin E acetate for the treatment of cheilitis: a multicentre experience. Eur J Inflamamm. 2003;1:125–128.
23. Madke B., Shah H., Singh A.L., et al. Oral retinoid-induced cheilitis. Ind J Drugs Dermatol. 2016;2:50–53.
24. Del Rosso J.Q. Clinical relevance of skin barrier changes associated with the use of oral isotretinoin: the importance of barrier repair therapy in patient management. J Drugs Dermatol. 2013;12(6):626–631.
25. Bettoli V., Guerra-Tapia A., Herane M.I., Piquero-Martin J. Challenges and solutions in oral isotretinoin in acne: reflections on 35 years of experience. Clin Cosmet Investig Dermatol. 2019;12:943–951. https://dx.doi.org/10.2147/CCID.S234231
26. Kmieć M.L., Pajor A., Broniarczyk-Dyła G. Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin. Postepy Dermatol Alergol. 2013;6:343–349. https://dx.doi.org/10.5114/pdia.2013.39432
27. Перламутров Ю.Н., Ольховская К.Б. Клиническая эффективность и профиль безопасности системного изотретиноина в терапии акне. Клиническая дерматология и венерология. 2020;19(5):730–736.
28. Melnik B.C. Overexpression of p53 explains isotretinoin’s teratogenicity. Exp Dermatol. 2018;27(1):91–93. doi:10.1111/exd.13420
29. Prevost N., English J.C. Isotretinoin: update on controversial issues. J Pediatr Adolesc Gynecol. 2013;26(5):290–293. https://dx.doi.org/10.1016/j.jpag.2013.05.007
30. Choi J.S., Koren G., Nulman I. Pregnancy and isotretinoin therapy. CMAJ. 2013;185(5):411–413. https://dx.doi.org/10.1503/cmaj.120729
31. Shin J., Cheetham T.C., Wong L., et al. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. J Am Acad Dermatol. 2011;65(6):1117–1125. https://dx.doi.org/10.1016/j.jaad.2010.09.017
32. Uusküla A., Pisarev H., Kurvits K., et al. Compliance with pregnancy prevention recommendations for isotretinoin in Estonia in 2012-2016. Drugs Real World Outcomes. 2018;5(2):129–136. https://dx.doi.org/10.1007/s40801-018-0135-z
33. Henry D., Dormuth C., Winquist B., et al. Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. CMAJ. 2016;188(10):723–730. https://dx.doi.org/10.1503/cmaj.151243
34. Crijns H.J.M.J., Straus S.M., Gispen-de Wied C., de Jong-van den Berg L.T.W. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol. 2011;164(2):238–244. https://dx.doi.org/10.1111/j.1365-2133.2010.09976.x
35. Albogami Y., Almadani O., Almohareb S.N., et al. Fetal exposure to isotretinoin in Saudi Arabia: a multicenter real-world data analysis from 2015 to 2020. Ther Adv Drug Saf. 2024;15:1–10. https://dx.doi.org/10.1177/20420986241272822
36. Alshiyab D., Marie H.B., Alrawashdeh R., et al. Assessing the impact of oral isotretinoin on the menstrual cycle: a prospective study on predictors of menstrual irregularities. Medicina (Kaunas). 2024;60(5):832. https://dx.doi.org/10.3390/medicina60050832
37. Dalgard F., Gieler U., Holm J.Ø., et al. Self-esteem and body satisfaction among late adolescents with acne: results from a population survey. J Am Acad Dermatol. 2008;59(5):746–751. https://dx.doi.org/10.1016/j.jaad.2008.07.013
38. Huang Y.C., Cheng Y.C. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;76(6):1068–1076.e9. https://dx.doi.org/10.1016/j.jaad.2016.12.028
39. Li C., Chen J., Wang W., et al. Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis. BMJ Open. 2019;9(1):e021549. https://dx.doi.org/10.1136/bmjopen-2018-021549
40. Fernandes T., Magina S. Oral isotretinoin in the treatment of juvenile acne and psychiatric adverse effects – a systematic review. Cutan Ocul Toxicol. 2023;42(3):83–90. https://dx.doi.org/10.1080/15569527.2023.2227889
41. Bremner J.D., Shearer K.D., McCaffery P.J. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry. 2012;73(1):37–50. https://dx.doi.org/10.4088/JCP.10r05993
42. Suarez B., Serrano A., Cova Y., Baptista T. Isotretinoin was not associated with depression or anxiety: a twelve-week study. World J Psychiatry. 2016;6(1):136–142. https://dx.doi.org/10.5498/wjp.v6.i1.136
43. Commission on Human Medicines. Report of the commission on human medicines isotretinoin implementation Advisory Expert Working Group. London: GOV.UK; 2023. Date of access: 20.06.2025. https://www.gov.uk/government/publications/report-of-the-commission-on-human-medicines-isotretinoin-implementation-advisory-expert-working-group
44. Shawky A., Elsheikh M., Elrewiny E.M., et al. Isotretinoin-induced hypersomnia: a cross-sectional study and literature review. Adv Skin Wound Care. 2024;37(8):1–3. https://dx.doi.org/10.1097/ASW.0000000000000187
45. Ismailogullari S., Ferahbas A., Aksu M., et al. Effects of isotretinoin treatment on sleep in patients with severe acne: a pilot study. J Eur Acad Dermatol Venereol. 2012;26(6):778–781. https://dx.doi.org/10.1111/j.1468-3083.2011.04095.x
46. Ruiz-Lozano R.E., Hernandez-Camarena J.C., Garza-Garza L.A., et al. Isotretinoin and the eye: a review for the dermatologist. Dermatol Ther. 2020;33(6):e14029. https://dx.doi.org/10.1111/dth.14029
47. Clayton J.A. Dry eye. N Engl J Med. 2018;378(23):2212–2223. https://dx.doi.org/10.1056/NEJMra1407936
48. Karaosmanoğlu N., Mülkoğlu C. Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study. BMC Musculoskelet Disord. 2020;21(1):631. https://dx.doi.org/10.1186/s12891-020-03656-w
49. Pehlivan Y., Kisacik B., Sayiner Z.A., Onat A.M. Inflammatory back pain in patients treated with isotretinoin. J Rheumatol. 2011;38(12):2690. https://dx.doi.org/10.3899/jrheum.110703
50. Eksioglu E., Oztekin F., Unlu E., et al. Sacroiliitis and polyneuropathy during isotretinoin treatment. Clin Exp Dermatol. 2008;33(2):122–124. https://dx.doi.org/10.1111/j.1365-2230.2007.02532.x
51. Barbareschi M., Paresce E., Chiaratti A., et al. Unilateral sacroiliitis associated with systemic isotretinoin treatment. Int J Dermatol. 2010;49(3):331–333. https://dx.doi.org/10.1111/j.1365-4632.2009.04334.x
52. Lebwohl B., Sundström A., Jabri B., et al. Isotretinoin use and celiac disease: a population-based cross-sectional study. Am J Clin Dermatol. 2014;15(6):537–542. https://dx.doi.org/10.1007/s40257-014-0090-8
53. Wright S., Strunk A., Garg A. Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin. J Am Acad Dermatol. 2021;84(1):41–45. https://dx.doi.org/10.1016/j.jaad.2020.07.042
54. Fraunfelder F.W., Fraunfelder F.T., Corbett J.J. Isotretinoin-associated intracranial hypertension. Ophthalmology. 2004;111(6):1248–1250. https://dx.doi.org/10.1016/j.ophtha.2003.09.044
55. Hareedy M.S., Tawfik K.M. Systemic isotretinoin has an impact on hemoglobin, ferritin, urea, ceruloplasmin, albumin, uric acid levels, and neutrophil to lymphocyte ratio in acne patients. J of Cosmetic Dermatology. 2022;21(11):6191–6198. https://dx.doi.org/10.1111/jocd.15199
Об авторах / Для корреспонденции
Кира Брониславовна Ольховская, к.м.н., доцент кафедры дерматовенерологии и косметологии, Центральная государственная медицинская академия Управления делами Президента РФ, Москва, Россия; olhovskaya_kira@mail.ru, ORCID: https://orcid.org/0000-0003-4920-5288, eLibrary SPIN: 9455-9482 (автор, ответственный за переписку)Лариса Сергеевна Круглова, д.м.н., профессор, зав. кафедрой дерматовенерологии и косметологии, ректор, Центральная государственная медицинская академия Управления делами Президента РФ, Москва, Россия; kruglovals@mail.ru, ORCID: https://orcid.org/0000-0002-5044-5265
Е.Е. Константиновская, Центральная государственная медицинская академия Управления делами Президента РФ, Москва, Россия; ORCID: https://orcid.org/0009-0000-9044-0672
Юлия Владимировна Кениксфест, д.м.н., доцент, зав. отделением хронических дерматозов для взрослых, Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии, Екатеринбург, Россия; keniksfest@mail.ru, ORCID: https://orcid.org/0000-0001-8431-5664
Также по теме
